LifeMD (NASDAQ:LFMD) Price Target Lowered to $6.00 at Mizuho

LifeMD (NASDAQ:LFMD) had its price objective decreased by analysts at Mizuho from $8.00 to $6.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. Mizuho’s price objective would suggest a potential upside of 50.00% from the company’s previous close.

A number of other research firms have also commented on LFMD. Wall Street Zen lowered shares of LifeMD from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Zacks Research raised LifeMD from a “strong sell” rating to a “hold” rating in a report on Friday, September 5th. KeyCorp reduced their price objective on LifeMD from $14.00 to $12.00 and set an “overweight” rating for the company in a research note on Wednesday, August 6th. Lake Street Capital decreased their price objective on LifeMD from $14.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday. Finally, BTIG Research dropped their target price on LifeMD from $18.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $10.57.

LifeMD Trading Down 2.2%

LFMD opened at $4.00 on Wednesday. The company has a quick ratio of 0.72, a current ratio of 0.77 and a debt-to-equity ratio of 9.21. LifeMD has a 52 week low of $3.43 and a 52 week high of $15.84. The business’s 50 day moving average is $6.01 and its two-hundred day moving average is $8.68. The firm has a market cap of $189.67 million, a price-to-earnings ratio of -23.54 and a beta of 1.57.

LifeMD (NASDAQ:LFMD) last posted its quarterly earnings data on Monday, November 17th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.04). The firm had revenue of $60.17 million during the quarter, compared to analyst estimates of $62.07 million. During the same period in the prior year, the firm earned $0.09 earnings per share. LifeMD has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, research analysts predict that LifeMD will post -0.56 EPS for the current year.

Insiders Place Their Bets

In other LifeMD news, insider Nicholas P. Alvarez sold 75,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $5.92, for a total transaction of $444,000.00. Following the transaction, the insider owned 605,000 shares in the company, valued at approximately $3,581,600. The trade was a 11.03% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 18.40% of the company’s stock.

Institutional Trading of LifeMD

Institutional investors have recently modified their holdings of the business. Arrowstreet Capital Limited Partnership lifted its holdings in LifeMD by 1,767.8% in the second quarter. Arrowstreet Capital Limited Partnership now owns 434,937 shares of the company’s stock valued at $5,924,000 after acquiring an additional 411,651 shares during the period. JPMorgan Chase & Co. grew its stake in shares of LifeMD by 581.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 412,571 shares of the company’s stock worth $5,619,000 after purchasing an additional 352,004 shares during the period. Jump Financial LLC increased its holdings in shares of LifeMD by 205.0% in the 2nd quarter. Jump Financial LLC now owns 515,052 shares of the company’s stock valued at $7,015,000 after purchasing an additional 346,171 shares in the last quarter. Invesco Ltd. lifted its stake in shares of LifeMD by 1,904.0% in the second quarter. Invesco Ltd. now owns 327,080 shares of the company’s stock valued at $4,455,000 after purchasing an additional 310,759 shares during the period. Finally, Nuveen LLC acquired a new stake in shares of LifeMD in the first quarter valued at about $1,545,000. 35.52% of the stock is currently owned by hedge funds and other institutional investors.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.